Company intelligence / Profile preview

Ropirio Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Ropirio Therapeutics has secured an exclusive license for novel lymphatic system activators and possesses a pioneering in vitro platform to model human lymphatic vessels. The company focuses on developing first-in-class medicines that directly target the lymph vessels for treating various diseases. Their programs are currently at the pre-clinical stage as of late 2024[1][3].

Therapeutic areas: HematologyRare Diseases
Modalities: Small moleculesgene editing therapies
Industry: Biotech

Drug pipeline

1 asset

Ropirio Therapeutics lymphatic system activator

Preclinical

Partnerships

Wyss Institute at Harvard University (spinout/launch partner)

Beyond the preview

Go deeper on Ropirio Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ropirio Therapeutics.

Explore the full profile